Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856279 | 1.00 | JAK1 (0.41) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL18668650 | 1.00 | JAK1 (0.41) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL24276487 | 1.00 | JAK1 (0.41) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL20397236 | 1.00 | JAK1 (0.41) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL22856045 | 0.86 | JAK1 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL18668743 | 0.83 | NR1H2 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL18668744 | 0.83 | NR1H2 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL20397175 | 0.83 | NR1H2 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL18247880 | 0.82 | NR1H2 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 | |
| SCHEMBL18247882 | 0.82 | NR1H2 (0.40) | JAK1NR1H2RORCUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| EP-3353181-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| EP-3353180-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050747-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050732-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | JAK1 3/4885NR1H2 2166/4885RORC 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.